EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action

Ludovica Migliozzi, Gian Paolo Fadini iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70443 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ludovica Migliozzi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Veneto Institute of Molecular Medicine, Laboratory of Experimental Diabetology, Padua, Italy. Hauptthemen laut MEDLINE: Metformin, Gastrointestinal Microbiome, Extracellular Traps, Hypoglycemic Agents. Die Arbeit nennt 98 Literaturangaben. Gefördert von: Ministry of University and Research PRIN, University of Padova 2017 STARS "DiaNEtes".

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin remains the most widely prescribed drug for diabetes management, yet recent studies have explored additional benefits, whose mechanisms are not completely understood. Recent research has highlighted the central role of the intestine in mediating metformin's therapeutic effects, involving interactions with the gut microbiota, intestinal epithelial cells, and the immune system. Among its various properties, metformin also exhibits immunomodulatory activity, drawing growing attention to its impact on neutrophil function. In particular, the excessive formation of neutrophil extracellular traps (NETs) and the process of NETosis have been linked to diabetes and its complications. Emerging evidence suggests that NETosis is influenced by alterations in gut microbiota composition and may itself contribute to metabolic dysregulation. This review explores intestinal NETosis as a novel and promising target of metformin, emphasizing its potential therapeutic relevance and the need for further investigation. A deeper understanding of these molecular pathways is essential to explore new therapeutic applications, guide the development of more personalized therapies that minimize adverse effects, and inspire next‐generation drugs that improve metformin's efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminGastrointestinal MicrobiomeExtracellular TrapsHypoglycemic AgentsDiabetes Mellitus, Type 2HumansAnimalsNeutrophilsIntestinal Mucosa

Stichwörter der Autor:innen

NETosisdiabetesdysmetabolismintestinal permeabilityintestinemetformin

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • Veneto Institute of Molecular Medicine, Laboratory of Experimental Diabetology, Padua, Italy.
  • Department of Medicine, University of Padova, Padua, Italy.

ORCID-Profile: Gian Paolo Fadini

Förderung

  • Ministry of University and Research PRIN
  • University of Padova 2017 STARS "DiaNEtes"

Zitieren

APA

Migliozzi, L., & Fadini, G. P. (2026). Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70443

Vancouver

Migliozzi L, Fadini GP. Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70443

BibTeX
@article{Migliozzi2026,
  author = {Migliozzi, Ludovica and Fadini, Gian Paolo},
  title = {Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70443}
}
Kostenlos starten →